细胞毒性药物市场 - 按类型、药物类别、给药途径、应用、配销通路- 全球预测 2024 - 2032

细胞毒性药物市场规模预计在 2024 年至 2032 年间复合年增长率为 5.4%。据世界卫生组织称，仅 2022 年，全球估计新增癌症病例 2,000 万例。在癌症治疗中越来越多地采用细胞毒性药物将对市场成长轨迹产生积极影响。药物开发和个人化医疗的重大进步也提高了细胞毒性药物的功效和安全性。

专注于新型细胞毒性药物製剂和联合疗法的不断扩大的研发活动正在增加这些药物的吸引力。医疗保健支出的增加、医疗保健基础设施的改善以及对癌症筛检和治疗选择的认识不断提高是鼓励产品采用的其他因素。

细胞毒性药物产业分为类型、药物类别、给药途径、应用、配销通路和区域。

根据类型，从 2024 年到 2032 年，仿製药领域的市场规模预计将以 6% 的复合年增长率增长。对负担得起的癌症治疗的需求不断增长以及仿製药公司不断扩大的市场渗透率也推动了该细分市场的成长。

按药物类别划分，由于植物源抗癌药物的广泛可用性和已被证实的功效，预计到 2032 年，植物生物碱领域的细胞毒性药物市场将以 4.9% 的增长率增长。植物生物碱，例如长春花生物碱和紫杉烷，对癌细胞表现出强大的细胞毒活性，使其成为化疗方案不可或缺的组成部分。正在进行的旨在发现具有抗癌特性的新型植物源化合物的研究也有助于该领域的扩张。

从地区来看，由于癌症盛行率不断上升，预计到 2032 年，欧洲细胞毒性药物产业将大幅成长。药物开发和个人化医疗的重大进步以及政府的支持政策正在促进癌症研究和治疗。不断增长的医疗支出和不断改善的医疗基础设施正在加速细胞毒性药物的采用。此外，主要市场参与者的存在以及製药公司和研究机构之间的合作将推动区域产业的扩张。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 全球癌症盛行率不断上升
    • 药物开发的技术进步
    • 老年人口不断增加
    • 联合疗法的采用率不断上升
  • 产业陷阱与挑战
    • 药物开发成本高
    • 不良反应和毒性
• 成长潜力分析
• 监管环境
• 技术景观
• 波特的分析
• PESTEL分析
• 报销场景
• 未来市场趋势
• 缺口分析

第 4 章：竞争格局

• 介绍
• 公司矩阵分析
• 公司市占率分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按类型，2018 - 2032

• 主要趋势
• 品牌药
• 仿製药

第 6 章：市场估计与预测：按药物类别，2018 - 2032 年

• 主要趋势
• 抗代谢药
• 抗肿瘤抗生素
• 植物生物碱
• 烷基化剂
• 其他药物类别

第 7 章：市场估计与预测：按管理途径，2018 年 - 2032 年

• 主要趋势
• 口服
• 注射用

第 8 章：市场估计与预测：按应用划分，2018 年 - 2032 年

• 主要趋势
• 肿瘤学
• 类风湿关节炎
• 多发性硬化症
• 其他应用

第 9 章：市场估计与预测：按配销通路划分，2018 年 - 2032 年

• 主要趋势
• 医院药房
• 零售药局
• 网路药局

第 10 章：市场估计与预测：按地区，2018 - 2032

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 义大利
  • 西班牙
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地区
• 中东和非洲
  • 沙乌地阿拉伯
  • 南非
  • 阿联酋
  • 中东和非洲其他地区

第 11 章：公司简介

• Amgen Inc.
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• Fresenius Kabi AG
• Merck & Co., Inc.
• Novartis AG
• Pfizer, Inc.
• Sanofi
• Teva Pharmaceutical Industries Ltd.

Cytotoxic Drugs Market size is estimated to depict 5.4% CAGR between 2024 and 2032. The increasing incidence of cancer worldwide is fueling the demand for cytotoxic drugs as primary or adjunctive therapies. According to WHO, in 2022 alone, the world witnessed an estimated 20 million new cancer cases. Increasing adoption of cytotoxic drugs in the treatment of cancer will positively influence the market growth trajectory. Significant advancements in drug development and personalized medicine are also enhancing the efficacy and safety profiles of cytotoxic agents.

The expanding R&D activities focused on novel cytotoxic drug formulations and combination therapies are increasing appeal of these drugs. The rising healthcare expenditure, improving healthcare infrastructure, and growing awareness about cancer screening and treatment options are other factors encouraging the product adoption.

The cytotoxic drugs industry is categorized into type, drug class, route of administration, application, distribution channel, and region.

Based on type, the market size from the generic drugs segment is estimated to grow at 6% CAGR from 2024 to 2032. The expiration of patents for branded cytotoxic medications is leading to the availability of cost-effective generic alternatives. The increasing demand for affordable cancer treatments and the expanding market penetration of generic pharmaceutical companies are also driving the segment growth ahead.

By drug class, the cytotoxic drugs market from the plant alkaloids segment is estimated to rise at 4.9% growth rate through 2032, owing to the wide availability and proven efficacy of plant-derived anticancer agents. Plant alkaloids, such as vinca alkaloids and taxanes, exhibit potent cytotoxic activity against cancer cells, making them integral components of chemotherapy regimens. The ongoing research aimed at discovering new plant-derived compounds with anticancer properties is also contributing to the segment expansion.

Regionally, the Europe cytotoxic drugs industry is projected to witness substantial gains by 2032, on account of the increasing prevalence of cancer. Significant advancements in drug development and personalized medicine, and supportive government policies are promoting cancer research and treatment. The rising healthcare expenditure and improving healthcare infrastructure are accelerating the adoption of cytotoxic drugs. Moreover, the presence of key market players and collaborations between pharmaceutical companies and research institutions will fuel the regional industry expansion.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definition
• 1.2 Base estimates & calculations
• 1.3 Data collection
• 1.4 Forecast calculations
• 1.5 Data sources
  • 1.5.1 Primary
  • 1.5.2 Secondary
    • 1.5.2.1 Paid sources
    • 1.5.2.2 Public sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of cancer worldwide
    • 3.2.1.2 Technological advancements in drug development
    • 3.2.1.3 Growing geriatric population
    • 3.2.1.4 Rising adoption of combination therapies
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High development costs of drugs
    • 3.2.2.2 Adverse effects and toxicity
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological landscape
• 3.6 Porter's analysis
  • 3.6.1 Supplier power
  • 3.6.2 Buyer power
  • 3.6.3 Threat of new entrants
  • 3.6.4 Threat of substitutes
  • 3.6.5 Industry rivalry
• 3.7 PESTEL analysis
• 3.8 Reimbursement scenario
• 3.9 Future market trends
• 3.10 Gap analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2018 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Branded drugs
• 5.3 Generic drugs

Chapter 6 Market Estimates and Forecast, By Drug Class, 2018 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Antimetabolites
• 6.3 Antitumor antibiotics
• 6.4 Plant alkaloids
• 6.5 Alkylating agents
• 6.6 Other drug classes

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2018 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Oral
• 7.3 Parenteral

Chapter 8 Market Estimates and Forecast, By Application, 2018 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Oncology
• 8.3 Rheumatoid arthritis
• 8.4 Multiple sclerosis
• 8.5 Other applications

Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2018 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 Hospital pharmacies
• 9.3 Retail pharmacies
• 9.4 Online pharmacies

Chapter 10 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Italy
  • 10.3.5 Spain
  • 10.3.6 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 China
  • 10.4.2 Japan
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
  • 10.4.6 Rest of Asia Pacific
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Argentina
  • 10.5.4 Rest of Latin America
• 10.6 Middle East and Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 South Africa
  • 10.6.3 UAE
  • 10.6.4 Rest of Middle East and Africa

Chapter 11 Company Profiles

• 11.1 Amgen Inc.
• 11.2 Bristol-Myers Squibb Company
• 11.3 Eli Lilly and Company
• 11.4 F. Hoffmann-La Roche Ltd.
• 11.5 Fresenius Kabi AG
• 11.6 Merck & Co., Inc.
• 11.7 Novartis AG
• 11.8 Pfizer, Inc.
• 11.9 Sanofi
• 11.10 Teva Pharmaceutical Industries Ltd.